Lifecore Biomedical has secured a new agreement with a global pharmaceutical company to provide technical transfer services for the commercial production of an injectable suspension targeting neurological disorders. This marks the company's seventh late-stage program deal in seven months, signaling strong business momentum for the CDMO. For overseas buyers and distributors, this underscores Lifecore's growing capacity in complex injectable manufacturing, a key consideration for sourcing sterile injectables.
Deal details
Lifecore Biomedical, Inc. (NASDAQ: LFCR) announced the agreement on June 15, 2026, from its headquarters in Chaska, Minnesota. Under the terms, Lifecore will perform technical transfer services to support the commercial production of an injectable suspension product for neurological disorders. The client is a global pharmaceutical company, though its identity was not disclosed.
Business momentum
This agreement represents Lifecore's seventh late-stage program agreement in seven months, indicating strong momentum in its business development efforts. CEO Paul Josephs emphasized that the partnership reflects confidence in Lifecore's manufacturing capabilities and quality, particularly for high-viscosity and complex pharmaceutical products.
Manufacturing capabilities
Lifecore is a fully integrated injectable contract development and manufacturing organization (CDMO) with over 40 years of experience. It specializes in sterile injectable pharmaceutical products, including complex formulations, and offers fill-and-finish services in syringes, vials, and cartridges. The company is also a leading manufacturer of premium, injectable-grade hyaluronic acid.
Sourcing context
For overseas importers and distributors of medical aesthetics injectables, Lifecore's track record in complex formulations and high-viscosity products is relevant. The company's expertise in sterile injectable manufacturing, including neurological suspensions, may appeal to buyers seeking reliable CDMO partners for specialty injectable products. However, the forward-looking statements in the announcement highlight inherent uncertainties in achieving anticipated growth and financial performance.
Source: Read the original report | Published: June 15, 2026